兴齐眼药品牌怎么样 申请店铺

我要投票 兴齐眼药在滴眼液行业中的票数:548 更新时间:2025-09-21
兴齐眼药是哪个国家的品牌?「兴齐眼药」是 沈阳兴齐眼药股份有限公司 旗下著名品牌。该品牌发源于辽宁省沈阳市,由创始人刘继东在1977-03-24期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力兴齐眼药品牌出海!将品牌入驻外推网,定制兴齐眼药品牌推广信息,可以显著提高兴齐眼药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

兴齐眼药怎么样

沈阳兴齐眼药股份有限公司是专业从事眼科药物研发、生产及销售的企业。公司成立三十多年来,秉承“经营健康、缔造光明”的企业理念,以“专心、专注、专业”的工作精神投入到人类眼健康产业。目前,公司拥有抗菌药、抗炎药、人工泪液、角膜修复药、抗疲劳药、散瞳药、手术用药、干眼治疗药等八大系列十五个产品,为眼科疾病治疗领域提供了高品质的产品。

创新是企业发展的动力和源泉。依托于企业技术中心和眼科药物工程技术研究中心,兴齐眼药建成了常规眼用制剂、即型凝胶、缓释制剂、药理与药代动力学等专业的眼科药物研究平台,具备综合的眼科药物研发创新能力。经过多年的持续创新和积累,截止到2014年,兴齐已拥有国家授权发明专利21项,国家授权外观设计专利2项,欧洲授权专利1项。

质量源于设计,优质的产品来自对细节的不断追求。2014年,兴齐眼药棋盘山工厂投入使用。工厂参照美国FDA和欧盟GMP标准设计,由设计团队、设备供应商及工程公司,通力合作建设完成。棋盘山工厂拥有滴眼剂、眼用凝胶剂、眼膏剂、眼内溶液剂、小牛血去蛋白提取物、眼用I类包材等七条生产线。

兴齐眼药营销中心设在北京,下设29个办事处,营销网络覆盖全国。兴齐眼药以客户为中心,服务于中国眼科医疗事业。2013年,兴齐眼药与中国医师协会眼科医师分会展开持续合作,资助基层一线的住院医师参加医学继续教育培训。兴齐眼药旨在通过一系列活动,鼓励广大中青年眼科医师深入钻研、不断创新,实现眼科医师整体水平的提升。

展望未来,机遇与挑战并存,日新月异的兴齐眼药将为做具有全球竞争力的眼科药物研究和制造企业坚持不懈、努力奋斗。


Shenyang Xingqi ophthalmic medicine Co., Ltd. is a company specializing in the research and development, production and sales of ophthalmic drugs. Since its establishment more than 30 years ago, the company has adhered to the enterprise philosophy of "operating health and creating brightness", and invested in the human eye health industry with the working spirit of "concentration, concentration and professionalism". At present, the company has eight series of 15 products, including antibacterial drugs, anti-inflammatory drugs, artificial tears, corneal repair drugs, anti fatigue drugs, mydriatic drugs, surgical drugs, dry eye treatment drugs, etc., providing high-quality products for the field of ophthalmic disease treatment. Innovation is the power and source of enterprise development. Relying on the center of enterprise technology and ophthalmic pharmaceutical engineering technology research center, Xingqi eye drops has been established as a research platform for ophthalmic drugs, including conventional ophthalmic preparation, instant gel, sustained release preparation, pharmacology and pharmacokinetics. After years of continuous innovation and accumulation, by 2014, Xingqi had 21 national authorized invention patents, 2 national authorized design patents and 1 European authorized patent. Quality comes from design, and quality products come from the constant pursuit of details. In 2014, Xingqi eye medicine Qishan factory was put into use. The factory is designed according to the US FDA and EU GMP standards, and completed by the design team, equipment suppliers and engineering companies. Chessboard Hill factory has eyedrops, ophthalmic gel, eye ointment, eye solution, calf blood protein extract, eye class I packaging and other seven production lines. Xingqi eye medicine marketing center is located in Beijing, with 29 offices and marketing network covering the whole country. Xingqi eye medicine is customer-centered and serves the ophthalmic medical industry in China. In 2013, Xingqi eye medicine launched continuous cooperation with ophthalmologist branch of Chinese Medical Doctor Association to support residents at the grassroots level to participate in medical continuing education and training. Through a series of activities, Xingqi eye medicine aims to encourage young and middle-aged ophthalmologists to further study and innovate, so as to improve the overall level of ophthalmologists. Looking forward to the future, opportunities and challenges coexist, and Xingqi ophthalmic will make unremitting efforts to be a globally competitive ophthalmic drug research and manufacturing enterprise.

本文链接: https://brand.waitui.com/1af9be86f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

山西汾酒:股东华创鑫睿计划减持不超1.33%公司股份

36氪获悉,山西汾酒发布公告,根据联和基金相关合作协议,其面临基金到期退出安排,需要减持其间接持有的全部公司股份,因此持股5%以上股东华创鑫睿本次拟通过大宗交易方式减持不超过1620.06万股(含本数),计划减持比例不超过1.33%;自本次减持计划公开披露之日起15个交易日后的3个月内(含3个月期满当日)实施。

40分钟前

中信证券:三方面的技术趋势将推动刻蚀设备的用量和重要性提升

36氪获悉,中信证券预计,至少以下三方面的技术趋势将推动刻蚀设备的用量和重要性提升:1.光刻多重图案化路线的采用;2.三维堆叠存储和近存计算需求;3.底层晶体管结构升级。长期看,半导体设备国产化方向明确,短期来看,下游扩产有望驱动行业进入新一轮增长期。建议关注国内刻蚀设备厂商以及相关配套设备、零部件企业机会。

40分钟前

中信证券:右侧趋势品种继续聚焦资源、消费电子、创新药和游戏

36氪获悉,中信证券研报表示,目前整体的行业选择框架依然是围绕资源+新质生产力+出海。资源股在供给受限以及全球地缘动荡的预期推动下,从周期属性转向偏红利属性会带来估值体系重构,博弈美联储降息的资金退潮带来的波动可以忽略。更大的中期线索还是中国制造业龙头的全球化,将份额优势转化为定价权和利润率提升,带来超越本国经济基本面的市值增长,从而逐步打破行情与基本面背离且全靠流动性驱动的错误认知。配置结构上,保持定力,右侧趋势品种继续聚焦资源、消费电子、创新药和游戏;左侧配置关注化工和军工;产业趋势层面,近期重点关注AI从云侧逻辑开始向端侧逻辑扩散。

40分钟前

环球印务:股东香港原石拟减持不超1%公司股份

36氪获悉,环球印务发布公告,持股10.98%的股份的股东香港原石国际有限公司(简称“香港原石”)计划以集中竞价交易合计减持不超过320.04万股公司股份,占公司总股本比例的1%。

40分钟前

冠中生态:筹划控制权变更事项,股票停牌

36氪获悉,冠中生态发布公告,公司控股股东青岛冠中投资集团有限公司及实际控制人李春林和许剑平正在筹划公司控制权变更相关事宜,可能导致公司控股股东及实际控制人发生变更。经申请,公司股票及可转换公司债券自2025年9月22日起停牌,预计停牌时间不超过2个交易日。停牌期间,公司可转换公司债券“冠中转债”将暂停转股。

40分钟前

本页详细列出关于兴齐眼药的品牌信息,含品牌所属公司介绍,兴齐眼药所处行业的品牌地位及优势。
咨询